National Pharmacy Health & Leadership Alliance Verify a MemberMember Login

What changed today in Metabolic: 3 trial updates, 1 new study

Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.

The signal

NPHLA tracked 4 new official records on this desk today: 3 trial updates, 1 new study.

Why this matters

GLP-1 and obesity-medicine developments can change access, supply, clinical evidence and patient conversations for clinics, pharmacies and prescribers.

What changed

  1. New trial registered: Effects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity[1]
  2. New trial registered: Study to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes[2]
  3. New research in Diabetes, obesity & metabolism: “Testosterone Added to Incretin Therapy in Men With Overweight or Obesity: A Systematic Review of Body Composition Evidence and Gaps”.[3]
  4. Trial status changed to “Active, not recruiting”: STAY SEC PsO (A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or…)[4]
  5. Also reported by Pharmacy Times: “Updates on Glucagon-Like Peptide-1 Receptor Agonists for Diabetes and Obesity”.[5]
  6. Also reported by Pharmacy Times: “Survodutide for Obesity and CV Risk: Liver, Lipids, and Beyond”.[6]
  7. Also reported by Pharmacy Times: “Semaglutide Cuts BMI in Young Children With Obesity in STEP Young”.[7]

Who this affects

  • Weight-management clinics
  • Med spas
  • Pharmacists
  • Prescribers
  • Medical directors
  • Practice owners & operators

What to watch next

No new verified deadlines in today’s records. See Deadline Watch for upcoming dates.

NPHLA takeaway

These are factual summaries of official records with no interpretation. Open the primary documents for full details; NPHLA editors add analysis where developments warrant it.

Source file

  1. [1]
  2. [2]
  3. [3]
  4. [4]
  5. [5]
    Updates on Glucagon-Like Peptide-1 Receptor Agonists for Diabetes and Obesity (opens the source in a new tab)

    News reportingPharmacy TimesIndustry coverage — headline and link only

  6. [6]
    Survodutide for Obesity and CV Risk: Liver, Lipids, and Beyond (opens the source in a new tab)

    News reportingPharmacy TimesIndustry coverage — headline and link only

  7. [7]
    Semaglutide Cuts BMI in Young Children With Obesity in STEP Young (opens the source in a new tab)

    News reportingPharmacy TimesIndustry coverage — headline and link only

Compiled automatically from primary official sources and peer-reviewed literature. Each line is a factual summary of a public record, linked to it — no interpretation is added. NPHLA links to sources and does not republish their text. Professional information only — not medical, legal or regulatory advice for any individual situation. Our standards.

Update timeline

  1. First published.
  2. Added 1 new official record.